Literature DB >> 18958437

[Gender differences in psychopharmacology].

V Regitz-Zagrosek1, C Schubert, S Krüger.   

Abstract

At least half of all patients with psychiatric disorders are female. Depressive disorders occur twice as often in women than in men. Despite the need for a gender-specific approach in treating psychiatric disorders, little is known about gender issues in psychopharmacology. It has been recognized that women respond better than men to serotonin-modulating substances but that this effect is reversed after menopause. Furthermore, women develop gynecological complications under medication with certain psychopharmacological agents which calls the use of these drugs into question. Side effects such as weight gain, hyperglycemia, cardiac arrhythmias, and sexual dysfunction also occur more frequently in women than in men. Pregnancy is a particularly sensitive aspect. The risk that a mother with a psychiatric disorder could relapse if the drug is discontinued has to be weighed against the risk of the child being born with an anomaly or developing prenatal complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18958437     DOI: 10.1007/s00108-008-2233-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  34 in total

Review 1.  Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment.

Authors:  J Kleiner; L Altshuler; V Hendrick; J M Hershman
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

Review 2.  On the association between valproate and polycystic ovary syndrome.

Authors:  P Genton; J Bauer; S Duncan; A E Taylor; A H Balen; A Eberle; B Pedersen; X Salas-Puig; M V Sauer
Journal:  Epilepsia       Date:  2001-03       Impact factor: 5.864

Review 3.  Course of mood and anxiety disorders during pregnancy and the postpartum period.

Authors:  L L Altshuler; V Hendrick; L S Cohen
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

4.  Effect of the menstrual cycle in ethanol pharmacokinetics.

Authors:  L Haddad; P Milke; L Zapata; J R de la Fuente; F Vargas-Vorácková; M Lorenzana-Jiménez; G Corte; J Tamayo; M Kaplan; M Márquez; D Kershenobich
Journal:  J Appl Toxicol       Date:  1998 Jan-Feb       Impact factor: 3.446

5.  Prescribing lithium for pregnant women.

Authors:  L S Cohen; J F Rosenbaum; V L Heller
Journal:  Am J Psychiatry       Date:  1988-06       Impact factor: 18.112

6.  Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.

Authors:  N A Kulin; A Pastuszak; S R Sage; B Schick-Boschetto; G Spivey; M Feldkamp; K Ormond; D Matsui; A K Stein-Schechman; L Cook; J Brochu; M Rieder; G Koren
Journal:  JAMA       Date:  1998-02-25       Impact factor: 56.272

7.  Changes in body mass index for individuals with and without schizophrenia, 1987-1996.

Authors:  Peter Homel; Daniel Casey; David B Allison
Journal:  Schizophr Res       Date:  2002-06-01       Impact factor: 4.939

8.  Osteoporosis in patients with schizophrenia.

Authors:  Martina Hummer; Peter Malik; Rudolf W Gasser; Alex Hofer; Georg Kemmler; Roy Cesar Moncayo Naveda; Maria A Rettenbacher; W Wolfgang Fleischhacker
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

9.  Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

Authors:  Veronica O'Keane; Anna Maria Meaney
Journal:  J Clin Psychopharmacol       Date:  2005-02       Impact factor: 3.153

10.  Toxic neonatal effects following maternal clomipramine therapy.

Authors:  M S Schimmell; E Z Katz; Y Shaag; A Pastuszak; G Koren
Journal:  J Toxicol Clin Toxicol       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.